RxDoctor Payments Data

Hassan Riaz, MD

Family Medicine · Paramount, CANPI 1336170075

Payments from drug & device makers

$262in general payments, 2019–2025

Across 15 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$53
  • Astellas Pharma US Inc$52
  • Novo Nordisk$37
  • Biohaven Pharmaceutical Holding Company Ltd.$24
  • Sanofi-aventis U.S. LLC$19
  • Amgen$19
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$262 in reported general payments places this provider in the 50th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$13,276
Medicare patients
55
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide69$90,236
JanuviaSitagliptin Phosphate58$89,834
OzempicSemaglutide50$52,479
FarxigaDapagliflozin Propanediol27$35,382
JardianceEmpagliflozin23$35,352
EliquisApixaban30$34,701
RybelsusSemaglutide21$23,127
XareltoRivaroxaban21$17,689
TradjentaLinagliptin11$15,088
Tresiba Flextouch U-200Insulin Degludec12$14,272
CreonLipase/Protease/Amylase12$10,896
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$7,736
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,927
Breo ElliptaFluticasone/Vilanterol15$5,461
Atorvastatin Calcium655$5,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$14$89,83458 claims
Novo NordiskOzempic, Rybelsus$37$75,60671 claims
AstraZenecaFarxiga$53$35,38227 claims
GSKBreo Ellipta$16$5,46115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 10,533 family medicine providers in California.

Other family medicine in Paramount

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →